Is the routine use of typhoid conjugate vaccines (TCVs) a cost-effective solution for countries? Should countries apply for TCV support from Gavi, the Vaccine Alliance? How should TCVs be introduced?

For most countries with a substantial typhoid burden, TCVs are cost-effective, but these questions are unique to every country and depend on several factors. To help decision-makers determine the best strategy for their country, TyVAC researchers conducted a health economic evaluation modeling different variables and their predicted effect on the costs, benefits, and cost-effectiveness of TCV. The results can be used to inform national decision-making for the introduction of TCVs.

Select your dataset

Launching will expand to maximize the browsing experience.

  1. World Overview – Explore an overview of predicted cost-effectiveness and vaccine impact modelling results for the 54 Gavi-eligible countries included in the analysis.
  2. Select a Country – Select a country from the map to see country-specific cost-effectiveness results, impact on disease burden, estimated vaccination costs, key input used and key drivers of the cost-effectiveness results. Adjust the inputs with the sliders to explore how the results might change according to different values.*
    * NOTE: For conjecture only; model input adjustments outside of published assumptions are not supported by evidence and any adjusted results- have not been corroborated by the researchers or TyVAC.
NOTE: The background, methods, results and discussion of this analysis are presented in detail in Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The content presented here should be considered together with this manuscript. Any changes to inputs away from those considered in the manuscript cannot be cited or referenced as such.
Photo: PATH/Madalitso Mvula.